Format

Send to

Choose Destination
Br J Haematol. 2018 Feb;180(4):484-500. doi: 10.1111/bjh.15032. Epub 2017 Nov 28.

Advances in targeted therapy for acute myeloid leukaemia.

Author information

1
Department of Internal Medicine V, University Hospital of Heidelberg, Heidelberg, Germany.
2
Clinical Cooperation Unit Molecular Haematology/Oncology, German Cancer Research Centre (DKFZ) and Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.
3
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.

Abstract

In the past few years, research in the underlying pathogenic mechanisms of acute myeloid leukaemia (AML) has led to remarkable advances in our understanding of the disease. Cytogenetic and molecular aberrations are the most important factors in determining response to chemotherapy as well as long-term outcome, but beyond prognostication are potential therapeutic targets. Our increased understanding of the pathogenesis of AML, facilitated by next-generation sequencing, has spurred the development of new compounds in the treatment of AML, particularly the creation of small molecules that target the disease on a molecular level. Various new agents, such as tyrosine kinase inhibitors, immune checkpoint inhibitors, monoclonal or bispecific T-cell engager antibodies, metabolic and pro-apoptotic agents are currently investigated within clinical trials. The highest response rates are often achieved when new molecularly targeted therapies are combined with standard chemotherapy. Presented here is an overview of novel therapies currently being evaluated in AML.

KEYWORDS:

BCL-2 inhibitor; acute myeloid leukaemia; immune-checkpoint inhibitors; targeted therapy; tyrosine kinase inhibitors

PMID:
29193012
PMCID:
PMC5801209
DOI:
10.1111/bjh.15032
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center